Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA)
The aim of the study was to evaluate the effect of the drug therapy assigned at the index visit on the risk of fatal outcome in outpatients with coronary heart disease within 24 months from the index visit, based on the data of registry of cardiovascular diseases (RECVASA). Follow-up feedback was 97...
Main Authors: | K. G Pereverzeva, S. S Yakushin, A. N Vorobyev, M. M Lukyanov, E. Yu Andreyenko, A. V Zagrebelny, A. D Deev |
---|---|
Format: | Article |
Language: | English |
Published: |
Concilium Medicum
2017-09-01
|
Series: | КардиоСоматика |
Subjects: | |
Online Access: | https://cardiosomatics.orscience.ru/2221-7185/article/viewFile/45348/pdf |
Similar Items
-
PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF OUTPATIENT REGISTRY RECVASA)
by: M. M. Loukianov, et al.
Published: (2017-05-01) -
Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
by: S R Gilyarevsky, et al.
Published: (2013-03-01) -
TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01) -
Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-06-01) -
Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
by: Naci Şenkal, et al.
Published: (2020-07-01)